Ionis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Ionis Pharmaceuticals Inc IONS.OQ reported quarterly adjusted earnings of 70 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of twenty two analysts for the quarter was for a loss of 43 cents per share. Wall Street expected results to range from $-1.17 to -2 cents per share.

• Revenue rose 100.7% to $452.00 million from a year ago; analysts expected $295.17 million.

• Ionis Pharmaceuticals Inc's reported EPS for the quarter was 70 cents​.

• The company reported quarterly net income of $124 million.

• Ionis Pharmaceuticals Inc shares had risen by 5.0% this quarter and gained 18.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 36.6% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 8 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $58.00, about 28.5% above its last closing price of $41.48

This summary was machine generated from LSEG data July 30 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)